Marko Hyvonen

Downing Ventures (Downing Ventures) is an independent venture capital firm founded in 1986. The firm is headquartered in London.

Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom.

Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom.

Pharmenable Ltd. operates as a drug discovery company. It designs the next generation of small molecule drugs. The company was founded by Hannah Fiona Sore, Natalia Mateu, Jelena Aleksic, David Spring, and Andreas Bender in June 2016 and is headquartered in Histon, the United Kingdom.

Spirea Ltd. operates as a healthcare technology company. It develops smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines. The company was founded by Myriam Ouberai and is headquartered in arrogate, the United Kingdom.

Part of Gas Sensing Solutions Ltd., Cambridge Respiratory Innovations Ltd. develops and manufactures medical devices. The private company is based in Swavesey, UK.

LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer.

SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK.